argenx SE: argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis

VYVGART is the first-and-only FDA-approved neonatal Fc receptor blocker 68% of anti-acetylcholine receptor (AChR) antibody positive gMG patients treated with VYVGART were responders (n=44/65)

Related Keywords

Japan ,United States ,Netherlands ,United Kingdom ,Israel ,Belgium ,China ,Switzerland ,France ,America ,Michelle Greenblatt ,Samantha Masterson ,Kelsey Kirk ,Jamesf Howard Jr ,Howard Jf Jr ,Steve Miller ,Beth Delgiacco ,Van Hauwermeiren ,Tim Van Hauwermeiren ,Department Of Neurology ,Linkedin ,Twitter ,Zai Lab ,Drug Administration ,Exchange Commission ,Myasthenia Gravis Foundation Of America ,Cigna ,European Medicines Agency ,Cigna Corp ,Devices Agency ,Japan Pharmaceuticals ,Immunology Innovation Program ,Myasthenia Gravis Activities ,Daily Living ,Business Wire ,Euronext Nasdaq ,Chief Executive Officer ,Myasthenia Gravis Foundation ,Neuromuscular Disease ,Allied Health ,North Carolina ,Chapel Hill School ,Principal Investigator ,Executive Vice President ,Chief Clinical Officer ,Authorization Applications ,Medical Devices Agency ,Greater China ,Important Safety Information ,Prescribing Information ,North America ,Generalized Myasthenia Gravis ,Therapeutics Targets ,Autoimmune Myasthenia ,Argenx ,Nnounces ,Wood ,Drug ,Administration ,Approval ,Vyvgart ,Efgartigimod ,Alfa ,Cab ,Generalized ,Myasthenia ,Ravis ,